Our Approved
Medicines
Our passion for scientific discovery led to two FDA-approved treatments for neurological conditions.
Our Products
We market two approved products in the United States.
The Product Information provided below is intended for residents of the U.S. only.
The Product Information provided below is intended for residents of the U.S. only.
Neurocrine Biosciences/AbbVie Collaboration
After discovering and developing elagolix through Phase 2 studies in endometriosis, we out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix. AbbVie launched ORILISSA® (elagolix tablets) in the United States and Canada in August and November 2018, respectively.
In June 2020, AbbVie launched ORIAHNN® (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States. We receive royalties at tiered percentage rates on AbbVie net sales of products containing elagolix.
*Links to a website owned by AbbVie Inc.
*Links to a website owned by AbbVie Inc.
Our
Responsibility
Responsibility
Our
Pipeline
Pipeline
